Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Kyle Moran Sells 15,630 Shares

Wave Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) CFO Kyle Moran sold 15,630 shares of the business's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $6.17, for a total transaction of $96,437.10. Following the completion of the transaction, the chief financial officer now directly owns 33,921 shares of the company's stock, valued at approximately $209,292.57. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Wave Life Sciences Trading Up 1.0 %

WVE stock traded up $0.06 during trading hours on Friday, hitting $5.91. 455,940 shares of the stock traded hands, compared to its average volume of 908,225. The stock has a 50-day simple moving average of $5.16 and a 200 day simple moving average of $5.22. Wave Life Sciences Ltd. has a one year low of $3.15 and a one year high of $7.67. The company has a market cap of $722.67 million, a P/E ratio of -10.75 and a beta of -1.12.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Wednesday, March 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $29.06 million for the quarter, compared to the consensus estimate of $23.30 million. During the same period in the prior year, the business earned ($0.47) EPS. Analysts forecast that Wave Life Sciences Ltd. will post -0.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on WVE shares. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $5.00 price objective on shares of Wave Life Sciences in a research note on Thursday, March 7th. Leerink Partnrs raised Wave Life Sciences from a "market perform" rating to an "outperform" rating in a research report on Tuesday, December 19th. StockNews.com lowered Wave Life Sciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday, January 18th. Truist Financial reissued a "buy" rating and issued a $17.00 price target on shares of Wave Life Sciences in a research note on Monday. Finally, SVB Leerink raised Wave Life Sciences from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $5.00 to $12.00 in a research note on Tuesday, December 19th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.14.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of WVE. M28 Capital Management LP grew its holdings in Wave Life Sciences by 4.7% in the 4th quarter. M28 Capital Management LP now owns 7,373,413 shares of the company's stock valued at $37,236,000 after buying an additional 328,913 shares during the last quarter. 683 Capital Management LLC grew its holdings in Wave Life Sciences by 0.5% in the 2nd quarter. 683 Capital Management LLC now owns 6,031,000 shares of the company's stock valued at $21,953,000 after buying an additional 31,000 shares during the last quarter. BlackRock Inc. grew its holdings in Wave Life Sciences by 227.8% in the 2nd quarter. BlackRock Inc. now owns 4,624,655 shares of the company's stock valued at $16,834,000 after buying an additional 3,213,732 shares during the last quarter. Kynam Capital Management LP grew its holdings in Wave Life Sciences by 3.1% in the 2nd quarter. Kynam Capital Management LP now owns 3,924,602 shares of the company's stock valued at $14,286,000 after buying an additional 116,726 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Wave Life Sciences in the 4th quarter valued at approximately $16,228,000. Institutional investors own 89.73% of the company's stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.